In the wake of COVID-19, the need for pandemic preparedness has become increasingly apparent. The Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network conducts basic and translational research on representative viruses within a specific virus family, with the goal of developing effective vaccines and monoclonal antibodies for other viruses within that family. By leveraging the “prototype pathogen” approach, the ReVAMPP network lay the groundwork for a faster and more effective pandemic response, should a virus from one of the targeted families emerge as a pandemic threat. Currently, there are no vaccines or targeted therapeutics for many diseases caused by the selected virus families.
The awards have been made to seven different US based research groups and one coordinating center. The Network works with NIAID, USG and global partners to share information and collaborate.
Main Areas of Focus
ReVAMPP is a pandemic preparedness research network designed to conduct fundamental basic through IND-enabling translational research on representative viruses, or “prototype pathogens,” within specific virus families. The virus families that the ReVAMPP network study contain many viruses that have caused human disease for millennia—many of which have a high likelihood of becoming pandemic threats in the future.
The ReVAMPP network focuses on viruses from the Flaviviridae family, which features viruses that cause dengue and yellow fever; the Paramyxoviridae family, which contains viruses that cause measles, mumps, and Nipah-induced encephalitis; the Picornaviridae family, whose members cause poliomyelitis, foot-and-mouth disease, and myocarditis; the Togaviridae family, which contains viruses that induce Chikungunya virus-induced arthralgia or encephalitis and Venezuelan equine encephalitis; as well as viruses from 5 different families within the Bunyavirales order, including Sin Nombre virus from the Hantaviridae family and the viruses that cause Rift Valley Fever (Phenuiviridae), Crimean Congo Hemorrhagic Fever (Nairoviridae), Oropouche Fever (Peribunyaviridae), and Lassa Fever (Arenaviridae):
The 9 viral families covered by the ReVAMPP network are:
- Flaviviridae
- Paramyxoviridae
- Picornaviridae
- Togaviridae
- Arenaviridae
- Hantaviridae
- Nairoviridae
- Phenuiviridae
- Peribunyaviridae
RTI International will lead a centralized Coordination and Data Sharing Center, to provide support and coordination for the network. By standardizing methodologies, such as reagents, animal models, and data outputs, research centers that comprise the ReVAMPP network are able to easily share their results and collaborate to enhance the network’s efforts.
Locations
The award recipients are:
Albert Einstein College of Medicine, Bronx, NY
Project title: PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats
Principal investigator: Kartik Chandran, Ph.D.
Grant: 1 U19 AI181977-01
Research Triangle Institute (RTI) International, Research Triangle Park, NC
Project title: Coordinating and Data Sharing Center - R&D of Vaccines and Antibodies for Pandemic Preparedness (ReVAMPP)
Principal investigator: Gregory D. Sempowski, Ph.D.
Grant: 1 UG3 AI181797-01
University of California, Irvine, CA
Project title: The UCI Vaccines for Pandemic Preparedness Center (VPPC)
Principal investigator: Louis Philip Felgner, Ph.D.
Grant: 1 U19 AI181968-01
University of Texas Medical Branch, Galveston, TX
Project title: Paramyxoviridae and Bunyavirales Vaccines and Antibodies Center (PABVAX)
Principal investigator: Thomas William Geisbert, Ph.D.
Grant: 1 U19 AI181930-01
University of Washington, Seattle, WA
Project title: Machine learning-enabled design of prototype pathogen vaccines and antibodies
Principal investigator: Neil King, Ph.D.
Grant: 1 U19 AI181881-01
Vanderbilt University Medical Center, Nashville, TN
Project title: Bunyavirus and Picornavirus Pandemic Pathogen Preparedness (BP4) Center
Principal investigator: James E. Crowe, Jr., M.D.
Grant: 1 U19 AI181979-01
Washington University, St. Louis, MO
Project title: Flavivirus and Alphavirus ReVAMPP (FLARE)
Principal investigator: Michael S. Diamond, M.D., Ph.D.
Grant: 1 U19 AI181960-01
Washington University, St. Louis, MO
Project title: Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPP
Principal investigator: Sean P.J. Whelan, Ph.D.
Grant: 1 U19 AI181984-01
View the ReVAMPP clinical/hospital/study and laboratory locations in a larger map
Contact Information
Pharmacy Professor Lands $3.6 Million Grant to Develop Phages Cocktail to Fight Bacteria
Virologist Aims at Halting Dangerous Neurological Effects of Powassan Virus
Vaccine Shows Promise in Treating High Blood Sugar for Those with Long COVID
T Helper Cells May Be the Key to Improving Annual Influenza Vaccines
HIV Prevention Medication Users Fear Being Stigmatized as “Promiscuous”
A Genetic Analysis of Bacteria Strains Causing Lyme Disease Could Transform Treatment
Brian Peters Part of Multi-Disciplinary Team Awarded $3.9 Million to Study Mixed Fungal-Bacterial Infections
NIH Awards Will Support Innovation in Syphilis Diagnostics
Contact
Submit a Media Request
Contact the NIAID News & Science Writing Branch.
The Antiviral Tecovirimat is Safe but Did Not Improve Clade I Mpox Resolution in Democratic Republic of the Congo
The antiviral drug tecovirimat did not reduce the duration of mpox lesions among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), based on an initial analysis of data from a randomized, placebo-controlled trial. However, the study’s 1.7% overall mortality among enrollees, regardless of whether they received the drug or not, was much lower than the mpox mortality of 3.6% or higher reported among all cases in the DRC. This shows that better outcomes among people with mpox can be achieved when they are hospitalized and provided high-quality supportive care.
Contact
Submit a Media Request
Contact the NIAID News & Science Writing Branch.